Outcomes of resected pancreatic cancer in patients age ≥70

Journal of Gastrointestinal Oncology

Volumn 6, Issue 5, 2015, Pages 498-504

  Hayman, Thomas J ^a   Strom, Tobin ^b   Springett, Gregory M ^b   Balducci, Lodovico ^b   Hoffe, Sarah E ^b   Meredith, Kenneth L ^c   Hodul, Pamela ^b   Malafa, Mokenge ^b   Shridhar, Ravi ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c SARASOTA MEMORIAL HOSPITAL   (United States)

Author keywords

Adjuvant therapy; Chemoradiation; Elderly; Pancreatic cancer; Surgery

Indexed keywords

CA 19-9 ANTIGEN; FLUOROURACIL; GEMCITABINE;

ADJUVANT CHEMOTHERAPY; AGE; AGED; ARTICLE; CANCER MORTALITY; CANCER SURGERY; CHEMORADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS CANCER; PANCREATICODUODENECTOMY; POSTOPERATIVE PERIOD; RADIATION DOSE;

EID: 84995752303     PISSN: 20786891     EISSN: 2219679X     Source Type: Journal    
DOI: 10.3978/j.issn.2078-6891.2015.038     Document Type: Article

References (24)

1. Vincent A, Herman J, Schulick R, et al. Pancreatic cancer. Lancet 2011;378:607-20.
2. Kanda M, Fujii T, Nagai S, et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas 2011;40:951-5.
3. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009;6:699-708.
4. Sehgal R, Alsharedi M, Larck C, et al. Pancreatic cancer survival in elderly patients treated with chemotherapy. Pancreas 2014;43:306-10.
5. Siegel R, Ma J, Zou Z, et al. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
6. Hoffe S, Rao N, Shridhar R. Neoadjuvant vs adjuvant therapy for resectable pancreatic cancer: the evolving role of radiation. Semin Radiat Oncol 2014;24:113-25.
7. Corsini MM, Miller RC, Haddock MG, et al. Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005). J Clin Oncol 2008;26:3511-6.
8. Herman JM, Swartz MJ, Hsu CC, et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008;26:3503-10.
9. Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:899-903.
10. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-85.
11. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-10.
12. Van Laethem JL, Hammel P, Mornex F, et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/ GERCOR phase II study. J Clin Oncol 2010;28:4450-6.
13. Thakkar JP, McCarthy BJ, Villano JL. Age-specific cancer incidence rates increase through the oldest age groups. Am J Med Sci 2014;348:65-70.
14. Kanda M, Fujii T, Suenaga M, et al. Pancreatoduodenectomy with portal vein resection is feasible and potentially beneficial for elderly patients with pancreatic cancer. Pancreas 2014;43:951-8.
15. Altekruse SF, Kosary CL, Krapcheco M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Available online: http://seer.cancer.gov/ csr/1975_2007/
16. Ries LA, Melbert D, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2005, National Cancer Institute. Bethesda, MD. Available online: http://seer.cancer.gov/ csr/1975_2005/, based on November 2007 SEER data submission, posted to the SEER web site, 2008.
17. Shore S, Vimalachandran D, Raraty MG, et al. Cancer in the elderly: pancreatic cancer. Surg Oncol 2004;13:201-10.
18. Balcom JH 4th, Rattner DW, Warshaw AL, et al. Tenyear experience with 733 pancreatic resections: changing indications, older patients, and decreasing length of hospitalization. Arch Surg 2001;136:391-8.
19. Cooper AB, Holmes HM, des Bordes JK, et al. Role of neoadjuvant therapy in the multimodality treatment of older patients with pancreatic cancer. J Am Coll Surg 2014;219:111-20.
20. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999;341:2061-7.
21. Aapro MS, Köhne CH, Cohen HJ, et al. Never too old? Age should not be a barrier to enrollment in cancer clinical trials. Oncologist 2005;10:198-204.
22. Garofalo MC, Regine WF, Tan MT. On statistical reanalysis, the EORTC trial is a positive trial for adjuvant chemoradiation in pancreatic cancer. Ann Surg 2006;244:332-3; author reply 333.
23. Miyamoto DT, Mamon HJ, Ryan DP, et al. Outcomes and tolerability of chemoradiation therapy for pancreatic cancer patients aged 75 years or older. Int J Radiat Oncol Biol Phys 2010;77:1171-7.
24. Horowitz DP, Hsu CC, Wang J, et al. Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2011;80:1391-7.